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Significance & InnovationsEthnicity‐specific expanded autoantibody profiles associate with lupus in Native American (NA), African American (AA), and European American (EA) cohorts.Rates of renal disease in AA patients with SLE were highest in a cluster characterized by high reactivity to the nucleosome components nucleolin and histone H1.Autoantibodies against Ro52 identify a cluster of NA patients with SLE with a trend toward higher rates of renal involvement.Autoantibodies against nucleolin/H1 in AA patients and H2A in EA patients identify subsets with increased disease severity.

INTRODUCTION {#acr211149-sec-0006}
============

Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by the development of autoantibodies toward a variety of cellular autoantigens ([1](#acr211149-bib-0001){ref-type="ref"}, [2](#acr211149-bib-0002){ref-type="ref"}, [3](#acr211149-bib-0003){ref-type="ref"}). Several autoantibodies develop in patients long before disease classification ([1](#acr211149-bib-0001){ref-type="ref"}), and autoantibodies play direct pathogenic roles ([4](#acr211149-bib-0004){ref-type="ref"}, [5](#acr211149-bib-0005){ref-type="ref"}, [6](#acr211149-bib-0006){ref-type="ref"}, [7](#acr211149-bib-0007){ref-type="ref"}, [8](#acr211149-bib-0008){ref-type="ref"}, [9](#acr211149-bib-0009){ref-type="ref"}, [10](#acr211149-bib-0010){ref-type="ref"}, [11](#acr211149-bib-0011){ref-type="ref"}, [12](#acr211149-bib-0012){ref-type="ref"}). Anti‐Ro/SSA autoantibodies are associated with cutaneous and hematologic manifestations as well as with neonatal lupus and congenital heart block in babies of anti‐Ro--positive mothers ([8](#acr211149-bib-0008){ref-type="ref"}, [9](#acr211149-bib-0009){ref-type="ref"}, [13](#acr211149-bib-0013){ref-type="ref"}, [14](#acr211149-bib-0014){ref-type="ref"}, [15](#acr211149-bib-0015){ref-type="ref"}). Anti--double‐stranded DNA (dsDNA) and anti‐Sm are associated with lupus nephritis ([11](#acr211149-bib-0011){ref-type="ref"}, [12](#acr211149-bib-0012){ref-type="ref"}), and anti‐dsDNA contributes to lupus nephritis pathogenesis ([16](#acr211149-bib-0016){ref-type="ref"}). Combinations of anti‐Ro, anti‐Sm, and anti‐RNP are associated with more severe forms of lupus ([2](#acr211149-bib-0002){ref-type="ref"}). Therefore, autoantibodies may provide information on biomarkers associated with the development of specific disease manifestations.

Various North American indigenous populations have higher incidence and prevalence rates of SLE ([17](#acr211149-bib-0017){ref-type="ref"}) and higher SLE mortality rates than other racial/ethnic groups ([18](#acr211149-bib-0018){ref-type="ref"}). Clinical SLE diagnosis may be more difficult in Native American (NA) patients because they are more likely to have concurrent rheumatic diseases or symptoms, including Raynaud phenomenon, interstitial lung disease, Sjӧgren syndrome, and systemic sclerosis, compared with patients of other races/ethnicities ([19](#acr211149-bib-0019){ref-type="ref"}). NA patients with SLE may also be more likely than European American (EA) patients to have severe manifestations of disease such as lupus nephritis ([19](#acr211149-bib-0019){ref-type="ref"}, [20](#acr211149-bib-0020){ref-type="ref"}) and hemolytic anemia ([19](#acr211149-bib-0019){ref-type="ref"}). Given the importance of autoantibodies in diagnosing and classifying disease manifestations, there is a need to identify autoantibody profiles that will be more useful in characterizing disease in NA patients with SLE.

The frequencies and titers of classical SLE autoantibodies vary among racial/ethnic groups. NA patients with SLE exhibited higher rates of anti‐dsDNA, anti‐Sm, anti‐RNP, anti‐Ro, and anti‐cardiolipin compared with EA patients but had lower rates of anti‐RNP compared with African American (AA) patients. Unknown specificities detected by precipitin are more common among NA patients with SLE than among AA, EA, or Hispanic patients with SLE ([19](#acr211149-bib-0019){ref-type="ref"}). Given the high frequency of precipitating levels of unknown specificities in NA patients with SLE, standard assays for detecting autoantibodies do not adequately define autoantibody profiles of the NA population with SLE. The number of different autoantibodies that have been identified in patients with SLE is much greater than the number of autoantibodies typically used for SLE clinical evaluation, diagnosis, and classification, suggesting that unique combinations of autoantibodies potentially exist that may allow for more thorough disease assessment across a broader range of racial populations ([3](#acr211149-bib-0003){ref-type="ref"}, [21](#acr211149-bib-0021){ref-type="ref"}).

Protein autoantigen arrays have been a useful tool for identifying additional autoantibodies in patients with SLE that are associated with disease manifestations such as lupus nephritis ([22](#acr211149-bib-0022){ref-type="ref"}, [23](#acr211149-bib-0023){ref-type="ref"}, [24](#acr211149-bib-0024){ref-type="ref"}). The goal of this discovery‐based study was to use protein autoantigen arrays to identify autoantibody specificities that may be informative for characterizing SLE in NA patients and to identify a set of autoantibodies that may be useful for identifying SLE patients with more severe disease.

PATIENTS AND METHODS {#acr211149-sec-0007}
====================

 {#acr211149-sec-0008}

### Cohorts and samples {#acr211149-sec-0009}

This study was approved by the institutional review boards of the Oklahoma Medical Research Foundation (OMRF) and the University of Oklahoma Health Sciences Center and was conducted in accordance with the Helsinki Declaration. All participants provided written informed consent prior to study‐specific procedures. Serum samples from 49 NA, 49 AA, and 49 EA age‐, sex‐, and antinuclear autoantibody (ANA) titer--matched patients with SLE and age‐ and sex‐ matched ANA‐negative control subjects from each ethnicity were selected from the Lupus Family Registry and Repository (LFRR) ([25](#acr211149-bib-0025){ref-type="ref"}). Individuals interested in participating in the LFRR directly contacted the OMRF for enrollment, and no recruitment occurred at tribal facilities. Demographics, including self‐reported race, were collected on questionnaires. Patients with SLE met both the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics classification criteria ([26](#acr211149-bib-0026){ref-type="ref"}, [27](#acr211149-bib-0027){ref-type="ref"}, [28](#acr211149-bib-0028){ref-type="ref"}). ACR criteria were extracted from patient medical records and used to calculate lupus severity index (LSI) scores as previously described ([29](#acr211149-bib-0029){ref-type="ref"}).

### Autoantibody assays {#acr211149-sec-0010}

Standardized serological tests were performed in the College of American Pathologists and Clinical Laboratory Improvement Amendments--certified OMRF Morris Reichlin Clinical Immunology Laboratory at the time of enrollment in the LFRR. ANAs were determined by indirect immunofluorescence with human epithelial type 2 cells and anti‐dsDNA autoantibodies by immunofluorescence against Crithidia (Inova Diagnostics). Precipitating levels of autoantibodies directed against Ro/SSA, La/SSB, Sm, RNP, and ribosomal P were detected by immunodiffusion ([30](#acr211149-bib-0030){ref-type="ref"}). Samples were also tested for 11 autoantibody specificities using an xMAP multiplex assay (BioPlex 2200; Bio‐Rad Technologies). The BioPlex 2200 ANA kit uses fluorescently labeled magnetic beads for the simultaneous detection of 11 autoantibody specificities, including dsDNA, ribosomal P, chromatin, Ro/SSA, La/SSB, Sm, the Sm/RNP complex, RNP, Jo‐1, Scl‐70, and centromere B. Serum verification beads specific for factor XIII are included in each reaction as a positive control (Bio‐Rad Technologies). Levels of Ro52 autoantibodies were confirmed by enzyme‐linked immunosorbent assay (ELISA) (Inova Diagnostics).

### Autoantigen arrays {#acr211149-sec-0011}

Serum samples were used to probe microarrays containing 123 autoantigens along with three immunoglobulin (Ig) and two anti‐Ig controls (University of Texas Southwestern, Microarray Core Facility). Autoantigens and control proteins were spotted in duplicate in a randomized manner onto nitrocellulose‐coated 16 pad Fast slides using a MicroGrid II microanalyzer as previously described ([23](#acr211149-bib-0023){ref-type="ref"}). Both IgM and IgG autoantibodies were detected using the appropriate fluorescent conjugated anti‐human IgG or IgM. Because only IgG reactivities were found to be informative for diagnosis and staging of disease, only IgG was analyzed for this study.

All arrays were scanned using the GenePix 4000B Microarray Scanner (Molecular Devices), and spot intensities were extracted using GenePix software (Molecular Devices). Background fluorescence was subtracted from the median fluorescence intensity for each reactivity. The resulting values were divided by the median fluorescence intensity of the Ig control spots; then the ratio was multiplied by 1000 to generate normalized fluorescence intensities (NFIs) for each autoantigen reactivity ([23](#acr211149-bib-0023){ref-type="ref"}, [24](#acr211149-bib-0024){ref-type="ref"}). To account for variability in total IgG levels, a relative NFI was calculated as the ratio of the NFI for each autoantigen to the total serum IgG spot NFI.

### Data availability {#acr211149-sec-0012}

Data generated during and/or analyzed during the current study are available from the corresponding author on reasonable request after approval by our institutions and tribal partners.

### Hierarchical clustering and statistical analysis {#acr211149-sec-0013}

Relative NFIs were transformed into *z* scores relative to all individuals in the same racial/ethnic cohort. For each reactivity, the mean NFI for all samples in the population (*μ*) was subtracted from the individual NFI (*x*), and the difference was divided by the population SD (*σ*):$$z = \frac{x - \mu}{\sigma}$$

To select autoantigens for use in clustering, we conservatively identified an autoantibody profile associated with SLE in each racial cohort. Autoantigen reactivities that differed between patients with SLE and race‐matched controls were determined by Kruskal‐Wallis analysis of the *z* scores (TIBCO Spotfire Analyst version 7.11.0.68; TIBCO Software); autoantigen reactivities with a *P* value of less than 0.06 were considered relevant for clustering. The *z* scores from the selected autoantibodies were used for hierarchical clustering of patients with SLE using TIBCO Spotfire Analyst version 7.11.0.68. Complete linkage was used as the hierarchical clustering method, and correlation was used as the distance measure. Clinical and serologic differences between patient populations and the enrichment of SLE clinical criteria within each cluster was determined by Fisher\'s exact test. To account for multiple comparisons, Kruskal‐Wallis analysis was followed by Dunn\'s post hoc test, and the false discovery method of Benjamini, Krieger, and Yekutieli was used for other analyses, with *q* values of less than 0.05 considered significant (GraphPad Prism version 8.3.1; GraphPad Software).

RESULTS {#acr211149-sec-0014}
=======

 {#acr211149-sec-0015}

### Demographics of study participants {#acr211149-sec-0016}

All groups were 90% women, with a median age of 45 years. There were no significant differences in age for patients with SLE or controls within a cohort or between cohorts (Table [1](#acr211149-tbl-0001){ref-type="table"}). ANA titers were similar among patients with SLE from all three ethnicities, and all controls were ANA negative by design (Table [1](#acr211149-tbl-0001){ref-type="table"}). The three cohorts showed similar autoantibody specificities by multiplex assay, except that AA patients had higher rates of anti‐SmRNP (71% in AA patients vs. 31% in EA patients; *q* = 0.0001) than EA patients and had higher rates of anti‐Sm (49% in AA patients vs. 18% in NA patients; *q* = 0.0053), anti‐SmRNP (71% in AA patients vs. 33% in NA patients; *q* = 0.0001) and anti‐RNP (61% in AA patients vs. 31% in NA patients; *q* = 0.0090) than NA patients ([Supplemental Table 1](#acr211149-sup-0001){ref-type="supplementary-material"}). The ACR criteria were similar among cohorts except for higher rates of malar rash in EA patients (59% in EA patients vs. 31% in NA patients; *q* = 0.0041; 29% in AA patients; *q* = 0.0041) and discoid rash in AA patients vs. NA patients (22% in AA patients vs. 4% in NA patients; *q* = 0.0305) ([Supplemental Table 1](#acr211149-sup-0001){ref-type="supplementary-material"}).

###### 

Demographics and ANA positivity of the study populations[a](#acr211149-note-0006){ref-type="fn"}

  Characteristics                                                  Native American   African American   European American                             
  ---------------------------------------------------------------- ----------------- ------------------ ------------------- ------------ ------------ ------------
  Age,[b](#acr211149-note-0007){ref-type="fn"} median (range), y   45 (27‐61)        45 (18‐73)         45 (27‐61)          45 (21‐72)   45 (27‐61)   45 (13‐72)
  Female sex, n (%)                                                9 (90)            44 (90)            9 (90)              44 (90)      9 (90)       44 (90)
  Anti‐ANA positive, n (%)                                         0 (0)             ...                0 (0)               ...          0 (0)        ...
  1:360[c](#acr211149-note-0008){ref-type="fn"}                    ...               15 (31)            ...                 15 (31)      ...          15 (31)
  1:1080[c](#acr211149-note-0008){ref-type="fn"}                   ...               15 (31)            ...                 16 (33)      ...          16 (31)
  1:3240[c](#acr211149-note-0008){ref-type="fn"}                   ...               12 (24)            ...                 12 (24)      ...          12 (26)
  1:9720[c](#acr211149-note-0008){ref-type="fn"}                   ...               7 (14)             ...                 6 (12)       ...          6 (12)

Abbreviation: ANA, antinuclear antibody; SLE, systemic lupus erythematosus.

Patients with SLE and controls were matched based on age, sex, and ANA titer.

The median ages of controls and patients with SLE within and across ethnicities were compared using the Kruskal‐Wallis test with Dunn\'s post hoc test for multiple comparisons; all *P* values \> 0.9999.

ANA titers of patients with SLE were compared across ethnicities using the Kruskal‐Wallis test with Dunn\'s post hoc test for multiple comparisons; all *P* values \> 0.9999.

John Wiley & Sons, Ltd

### Identification of expanded autoantibody profiles associated with lupus in NA, AA, and EA cohorts {#acr211149-sec-0017}

Because the classical autoantibodies used for diagnosing and classifying lupus are not represented the same in NA patients with SLE as in patients with SLE from other ethnicities, we used expanded autoantigen arrays to identify lupus‐associated autoantibody profiles in NA, AA, and EA cohorts. Out of 123 autoantigens representing nuclear, extracellular matrix, cytoplasmic/membrane, circulating, microfilament, and pathogen‐associated proteins ([Supplemental Table 2 and Supplemental Table 3](#acr211149-sup-0001){ref-type="supplementary-material"}), the lupus‐associated autoantibody profiles included 18 autoantigens in the NA cohort, 29 autoantigens in the AA cohort, and 22 autoantigens in the EA cohort (bolded *P* values in [Supplemental Table 2](#acr211149-sup-0001){ref-type="supplementary-material"}).

All of the ethnicity‐specific autoantibody profiles included nuclear autoantibodies commonly associated with SLE (chromatin, dsDNA, single‐stranded DNA \[ssDNA\], genomic DNA, nucleosome antigen, Ribo P0, Ro52/SSA, and single‐stranded RNA \[ssRNA\]) as well as the extracellular matrix autoantigens collagen VI and heparin ([Supplemental Table 2](#acr211149-sup-0001){ref-type="supplementary-material"}). In addition, the NA‐specific SLE autoantibody profile included increased reactivity to the nuclear autoantigens PM/Scl‐100 and Ribo P1 ([Supplemental Table 2](#acr211149-sup-0001){ref-type="supplementary-material"}) and the neutrophil granule‐associated protein myeloperoxidase as well as decreased reactivity to the extracellular matrix autoantigens heparan HSPG, heparan sulfate, laminin, matrigel, and proteoglycan compared with NA controls ([Supplemental Table 2](#acr211149-sup-0001){ref-type="supplementary-material"}). The AA‐specific SLE autoantibody profile included increased reactivity to histone proteins (H1 and H3), nucleolin, members of the Sm/RNP complex (Sm, SmD, SmD1, SmD3, Sm/RNP, U1‐snRNP‐A, U1‐snRNP‐BB', U1‐snRNP‐C, and U1‐snRNP‐68), extracellular matrix molecules (entactin and fibronectin), M2 protein, muscarinic receptor, complement C5, and α‐actinin compared with AA controls ([Supplemental Table 2](#acr211149-sup-0001){ref-type="supplementary-material"}). The EA‐specific SLE autoantibody profile also included increased reactivity to PM/Scl‐100, histone proteins (H1, H2A, and H2B), members of the Sm/RNP complex (SmD, U1‐snRNP‐A, U1‐snRNP‐BB', U1‐snRNP‐C, and U1‐snRNP‐68) ([Supplemental Table 2](#acr211149-sup-0001){ref-type="supplementary-material"}), entactin, α‐actinin, and the Epstein‐Barr virus EBNA1 protein ([Supplemental Table 2](#acr211149-sup-0001){ref-type="supplementary-material"}) compared with EA controls. Autoantigen reactivities that did not vary significantly between NA, AA, or EA patients with SLE and their controls are listed in [Supplemental Table 3](#acr211149-sup-0001){ref-type="supplementary-material"}.

### Hierarchical clustering of NA, AA, and EA patients with SLE using NA‐, AA‐, and EA‐specific lupus‐associated autoantibody profiles {#acr211149-sec-0018}

To identify subsets of patients with SLE with similar autoantigen reactivity, the ethnicity‐specific autoantibody profiles were used to perform hierarchical clustering of NA, AA, and EA patients with SLE. Using this approach, four distinct clusters of patients with SLE were identified for each ethnicity (Figure [1](#acr211149-fig-0001){ref-type="fig"}). The clusters showed no significant differences in ANA titers ([Supplemental Figure 2](#acr211149-sup-0001){ref-type="supplementary-material"}) but had different patterns of autoantigen reactivity (Figures [1](#acr211149-fig-0001){ref-type="fig"} and [2](#acr211149-fig-0002){ref-type="fig"}).

![Hierarchical clustering of Native American (NA), African American (AA), and European American (EA) patients with systemic lupus erythematosus (SLE) using disease‐associated reactivity on a directed autoantigen array. Autoantigens with different reactivity (*P* \< 0.06) between patients and ethnicity‐matched controls were selected for hierarchical clustering of NA,AA, and EA patients with SLE. Four clusters in each cohort were identified based on *z* scores representing autoantigen reactivity (see Methods). The *z* scores are shown on a gradient scale with maximum autoantigen reactivity in red, average reactivity in gray, and minimum reactivity in blue. Clusters were named after their most distinct autoantibodies (NA clusters: Ro52 \[n = 9\], ECM1 \[n = 12\], ECM2 \[n = 12\], and nucleic acid \[n = 16\]; AA clusters: Ro52 \[n = 8\], nucleic acid \[n = 8\], Sm/RNP \[n = 16\], and nucleolin/H1 \[n =1 7\]; EA clusters: histone 2A low \[n = 11\], Ro52 \[n = 14\], histone 2A high \[n = 14\], and nucleic acid \[n = 10\]). Ag, antigen; dsDNA, double‐stranded DNA; ECM, extracellular matrix; ssDNA, single‐stranded DNA; ssRNA, single‐stranded RNA.](ACR2-2-415-g001){#acr211149-fig-0001}

![Autoantibody enrichment observed in Native American, African American, and European American systemic lupus erythematosus patient clusters. Autoantibody levels in each sample were calculated as a ratio of the normalized fluorescence intensity divided by the total serum immunoglobulin G for that sample. The median autoantibody levels in each cluster are shown using a log~10~ scale, using the color schemes as shown. Autoantibody levels that differed significantly between clusters were determined by Kruskal‐Wallis analysis with Dunn\'s post hoc test. Colored arrows indicate clusters with significantly higher (up arrows) autoantibody levels compared with the clusters indicated by colored dots. *P* values are provided in the text. Ag, antigen; dsDNA, double‐stranded DNA; HSPG, heparan sulfate proteoglycans; Rec, receptor; ssDNA, single‐stranded DNA; ssRNA, single‐stranded RNA.](ACR2-2-415-g002){#acr211149-fig-0002}

One cluster of patients with SLE from each ethnicity was characterized by higher reactivity to Ro52 (Figures [1](#acr211149-fig-0001){ref-type="fig"} and [2](#acr211149-fig-0002){ref-type="fig"}). The Ro52 clusters in the NA and EA cohorts had significantly higher reactivity to Ro52 compared with the other three clusters in the same cohorts (Figures [1](#acr211149-fig-0001){ref-type="fig"} and [2](#acr211149-fig-0002){ref-type="fig"}). In the AA cohort, the Ro52 cluster had significantly higher reactivity to Ro52 than the SmRNP cluster and had a nonsignificant increase in Ro52 reactivity compared with the nucleolin/H1 and nucleic acid clusters (Figures [1](#acr211149-fig-0001){ref-type="fig"} and [2](#acr211149-fig-0002){ref-type="fig"}). Results of a Ro52‐specific ELISA ([Supplemental Figure 1](#acr211149-sup-0001){ref-type="supplementary-material"}) were consistent with increased reactivity to Ro52, particularly in the NA and EA Ro52 clusters.

A second cluster of patients with SLE from each ethnicity was characterized by higher reactivity to nucleic acids, with higher reactivity to chromatin, dsDNA, ssDNA, and ssRNA compared with the other clusters (Figures [1](#acr211149-fig-0001){ref-type="fig"} and [2](#acr211149-fig-0002){ref-type="fig"}). The nucleic acid clusters in the NA and EA cohorts also had significantly higher reactivity to genomic DNA (Figures [1](#acr211149-fig-0001){ref-type="fig"} and [2](#acr211149-fig-0002){ref-type="fig"}). In addition, the nucleic acid clusters in the AA and EA cohorts, but not in the NA cohort, had significantly higher reactivity to heparin, α‐actinin, and collagen VI compared with the other clusters in the same cohort (Figures [1](#acr211149-fig-0001){ref-type="fig"} and [2](#acr211149-fig-0002){ref-type="fig"}).

The third and fourth clusters of NA patients with SLE, designated ECM1 and ECM2, had significantly higher reactivity to different sets of extracellular matrix autoantigens compared with the other clusters (Figures [1](#acr211149-fig-0001){ref-type="fig"} and [2](#acr211149-fig-0002){ref-type="fig"}). The ECM1 NA patient cluster had higher reactivity to proteoglycan (*P* = 0.0435 vs. the Ro52 NA patient cluster and *P* = 0.0156 vs. nucleic acid NA patient clusters). The ECM2 NA patient cluster had higher reactivity to heparan HSPG (*P* \< 0.0001 vs. the Ro52 cluster, *P* = 0.0005 vs. the ECM1 cluster, and *P* = 0.0078 vs. the nucleic acid cluster), laminin (*P* = 0.0004 vs. the Ro52 cluster, *P* = 0.0105 vs. the ECM1 cluster, and *P* \< 0.0001 vs. the nucleic acid cluster), and matrigel (*P* = 0.0023 vs. the Ro52 cluster and *P* = 0.0026 vs. the ECM1 cluster). Both the ECM1 and ECM2 NA patient clusters had higher reactivity to heparan sulfate compared with the nucleic acid NA patient cluster (Figures [1](#acr211149-fig-0001){ref-type="fig"} and [2](#acr211149-fig-0002){ref-type="fig"}). Reactivity to myeloperoxidase trended higher in the ECM1 cluster (*P* = 0.0865 vs. the Ro52 cluster and *P* = 0.0547 vs. the nucleic acid cluster).

The third cluster of AA patients with SLE, designated the SmRNP cluster, had high reactivity to Sm (*P* = 0.0053 vs. the Ro52 cluster), SmRNP (*P* = 0.0066 vs. the Ro52 cluster and *P* = 0.0277 vs. the nucleolin/histone H1 cluster), and SmD (*P* = 0.0085 vs. the Ro52 cluster). Additionally, the SmRNP cluster had higher reactivity to complement C5 (*P* = 0.0137 vs. the nucleolin/histone H1 cluster) (Figures [1](#acr211149-fig-0001){ref-type="fig"} and [2](#acr211149-fig-0002){ref-type="fig"}). The fourth cluster of AA patients with SLE, designated the nucleolin/H1 cluster, had high reactivity to histone H1 (*P* = 0.0069 vs. the Ro52 cluster), nucleolin (*P* = 0.0002 vs. the Ro52 cluster; *P* = 0.0012 vs. the NA cluster, and *P*=0.0086 vs. the SmRNP cluster) (Figures [1](#acr211149-fig-0001){ref-type="fig"} and [2](#acr211149-fig-0002){ref-type="fig"}).

The additional EA SLE clusters, designated H2A high and H2A low, had either significantly higher or significantly lower reactivity to histone H2A, respectively (*P* = 0.0120) (Figures [1](#acr211149-fig-0001){ref-type="fig"} and [2](#acr211149-fig-0002){ref-type="fig"}). The EA SLE H2A high patients also had significantly higher levels of reactivity to histone H2A (*P* = 0.0113 vs. the Ro52 cluster), histone H2B (*P* = 0.0079 vs. the Ro52 cluster), U1‐snRNP68 (*P* = 0.0025 vs. the Ro52 cluster), U1‐snRNPC (*P* = 0.0082 vs. the Ro52 cluster), heparin (*P* = 0.0356 vs. the Ro52 cluster), entactin (*P* = 0.0018 vs. the Ro52 cluster), and α‐actinin (*P* = 0.0035 vs. the Ro52 cluster) (Figures [1](#acr211149-fig-0001){ref-type="fig"} and [2](#acr211149-fig-0002){ref-type="fig"}).

Renal manifestations of SLE are significantly higher in the nucleolin/histone H1 cluster for AA patients with SLE and trend higher in the Ro52 cluster for NA patients with SLE and the H2A cluster of EA patients with SLE.

### Disease manifestations in NA, AA, and EA patients with SLE clustered by expanded autoantibody profiles {#acr211149-sec-0019}

To determine whether autoantibody profiles were associated with differences in disease manifestations within SLE cohorts, we compared the ACR criteria and disease severity between patient clusters within each ethnicity. Among NA patients with SLE, the Ro52 cluster had a high rate of renal disease, but this did not reach significance when correcting for multiple comparisons (55.6% in the Ro52 cluster vs. 16.7% in the ECM1 cluster \[*P* = 0.0873\] and 8.3% in the ECM2 cluster \[*P* = 0.0464; *q* = 0.2750\]) (Figure [3](#acr211149-fig-0003){ref-type="fig"}A and [Supplemental Table 4](#acr211149-sup-0001){ref-type="supplementary-material"}). Although dsDNA has been associated with lupus nephritis, the Ro52 cluster of NA patients did not exhibit increased reactivity to dsDNA in the autoantigen array (Figure [2](#acr211149-fig-0002){ref-type="fig"}) or high rates of anti‐dsDNA by multiplex (11.1% vs. 8.3%‐25.0%) or indirect immunofluorescence (22.2% vs. 8.3%‐75%) ([Supplemental Table 4](#acr211149-sup-0001){ref-type="supplementary-material"}). Rates of other ACR criteria did not differ between clusters of NA patients, and no clusters showed differences in length of disease ([Supplemental Figure 3](#acr211149-sup-0001){ref-type="supplementary-material"}). The LSI did not differ between clusters (Figure [3](#acr211149-fig-0003){ref-type="fig"}B).

![Renal manifestations in the Native American Ro52 and the African American nucleolin/H1 patient clusters. **A**, The percentage of patients with systemic lupus erythematosus in each patient cluster that met the American College of Rheumatology (ACR) criteria for renal disease was determined from data extracted from medical records. Enrichment for renal activity in clusters was determined using Fisher\'s exact test and *q* values calculated by the false discovery method. **B**, The lupus severity index (LSI) score for each patient was calculated using ACR data extracted from medical records. The median LSI score for each cluster was compared using Kruskal‐Wallis analysis with Dunn\'s post hoc test. *P* values of less than 0.05 are indicated.](ACR2-2-415-g003){#acr211149-fig-0003}

Among AA patients with SLE, the nucleolin/H1 cluster had significantly higher rates of renal involvement and significantly higher LSI scores than the SmRNP cluster (Figure [3](#acr211149-fig-0003){ref-type="fig"} and [Supplemental Table 5](#acr211149-sup-0001){ref-type="supplementary-material"}). Other differences between AA clusters did not reach significance (Figure [3](#acr211149-fig-0003){ref-type="fig"} and [Supplemental Table 5](#acr211149-sup-0001){ref-type="supplementary-material"}). Among EA patients with SLE, individual ACR criteria showed no significant differences between clusters, but the H2A cluster had significantly higher disease severity compared with the Ro52 cluster using the LSI (Figure [3](#acr211149-fig-0003){ref-type="fig"} and [Supplemental Table 6](#acr211149-sup-0001){ref-type="supplementary-material"}).

DISCUSSION {#acr211149-sec-0020}
==========

Current tools used to detect autoantibodies for SLE diagnosis and classification were largely developed with study cohorts in which NA populations were underrepresented ([31](#acr211149-bib-0031){ref-type="ref"}). As a result, these tests are not optimal for identifying informative autoantibody specificities for NA patients with rheumatic disease, and there is a need to identify autoantibody profiles that will facilitate the development of diagnostic and disease‐monitoring tools that are more appropriate for NA patients with SLE.

This study builds on previous work that used autoantigen arrays to identify autoantibodies associated with lupus nephritis and to differentiate patients with SLE from those with incomplete SLE ([22](#acr211149-bib-0022){ref-type="ref"}, [23](#acr211149-bib-0023){ref-type="ref"}, [24](#acr211149-bib-0024){ref-type="ref"}). We utilized autoantigen arrays to define a novel autoantigen reactivity profile that associates with SLE in a NA cohort and reveals clusters of patients with SLE defined by distinct patterns of autoantigen reactivity. The cluster of NA patients characterized by increased Ro52 reactivity had a trend toward higher rates of renal disease, which was not significant after correcting for multiple comparisons. The time since diagnosis also trended higher in the Ro52 cluster of NA patients with SLE but did not differ significantly compared with the other NA SLE patient clusters. Renal disease in the Ro52 cluster of NA patients was not explained by anti‐dsDNA, which is typically associated with lupus nephritis, because the Ro52 cluster had significantly lower levels of anti‐dsDNA ([4](#acr211149-bib-0004){ref-type="ref"}, [7](#acr211149-bib-0007){ref-type="ref"}, [11](#acr211149-bib-0011){ref-type="ref"}, [12](#acr211149-bib-0012){ref-type="ref"}, [32](#acr211149-bib-0032){ref-type="ref"}, [33](#acr211149-bib-0033){ref-type="ref"}). Interestingly, recent publications demonstrated that anti‐Ro autoantibodies, in combination with anti--early apoptotic cell autoantibodies, were linked to poor outcomes in patients with SLE and nephritis ([34](#acr211149-bib-0034){ref-type="ref"}) and that Ro52‐positive patients with SLE and higher levels of serum calreticulin had higher disease activity ([35](#acr211149-bib-0035){ref-type="ref"}). Therefore, further exploration with a larger population of NA patients with SLE is warranted to clarify the potential relevance of Ro52 antibodies to renal disease in NA patients.

In the AA cohort, renal disease was most common in the cluster characterized by higher reactivity to the nucleosome components nucleolin and histone H1, with no increases in anti‐dsDNA. This result might not be surprising, considering that autoantibodies to nucleosomes have been associated with renal disease ([32](#acr211149-bib-0032){ref-type="ref"}). This cluster of AA patients with SLE also had significantly higher LSI scores than the other AA SLE patient clusters.

Unlike the Ro52 cluster of NA patients, the Ro52 cluster of EA patients had low rates of renal disease and significantly lower LSI scores compared with the H2A high cluster of EA patients with SLE. The H2A high cluster exhibited the highest LSI scores and a trend toward increased renal disease compared with the other EA patient clusters. The H2A cluster showed equal levels of reactivity to dsDNA.

These results identify interesting differences between the lupus‐associated autoantibody profiles in NA, AA, and EA patients with SLE, and additional analysis of expanded autoantigens may support more equitable tools for characterizing SLE in these different populations. Indeed, others have suggested that autoantibodies traditionally associated with SLE are not the only autoantibodies that should be considered, nor should they be considered alone when identifying the best biomarkers of SLE with renal manifestations ([36](#acr211149-bib-0036){ref-type="ref"}, [37](#acr211149-bib-0037){ref-type="ref"}). Because of the discovery‐based study design with a large number of comparisons and a relatively small sample size, our findings require confirmation in larger studies designed for hypothesis testing. Additionally, because some of these findings may be influenced by genetic admixture, ideally our observations need to be confirmed in a larger cohort of NA, AA, and EA patients with SLE whose races/ethnicities have been established by pedigree analysis rather than self‐report. Furthermore, analysis of expanded autoantibody profiles in a longitudinal cohort with detailed disease activity assessments, such as Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) or SLEDAI‐2K scores, would provide more robust data for understanding the value of autoantibody profiles for prognostic assessments.

In summary, the results of our study demonstrate that an expanded autoantibody profile can be used to identify informative autoantibodies for SLE patient populations that have been traditionally underrepresented in biomarker development.
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